HIGHLIGHTS
- who: Matthew J. Kling from the Department of Pediatrics, Hematology and Oncology Division, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE, USA have published the paper: A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma, in the Journal: (JOURNAL)
- what: The authors show that combined inhibition of BET proteins by JQ1 or OTX015 and HDACs by panobinostat triggered broad antitumor activities in MYC-driven MB, both in_vitro and in_vivo. This study provides the first preclinical evidence for the therapeutic potential of dual-targeting BET and HDACs . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.